Drug Submission time again. We are looking to speak to anyone who has experience of Loratinib (Lorviqua)

[NicF4]

lorlatinib (Lorviqua) will shortly be assessed by the Scottish Medicines Consortium (SMC) for use in NHSScotland, and to invite you to provide a Patient Group Submission for the medicine.

The indication this new medicine will be assessed under is: "As monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: Alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or Crizotinib and at least one other ALK TKI".

We do not need to include any personal details in the submission. But speaking to those with experience of the treatment and obtaining quotes for the submission is the most important part of the submission.

Please either leave a reply, PM me, or phone our helpline on 08003587200

Regards

Nicky

[Hanl]

Hi

What sort of information is it you need? My dad is currently taking lorlatinib after being on both crizotinib and ceritinib. I could have a word with him and see if he’s willing to participate.

[NicF4 Partner Roy Castle in reply to Hanl]

Hi Hanl

I don't need to include any personal information. If you and your dad would be happy to speak to me over the phone that would be great. I really only need to know from both the patient and family perspective how well your dad is tolerating the drug and what impact it is having on daily life and family life. if you are happy for me to email you, I can email you a list of questions if that's easier? examples are: If your dad has had other treatments how does it compare? are the side effects manageable?

Thanks

Nicky